Hot Investor Mandate: USA-Based VC Firm Seeks to Invest in Seed to Series B Companies that Target Better Care Delivery and Diagnosis, AI-Driven Drug Discovery, and More

28 Sep

A women-led venture capital firm headquartered in the US is led by a team that brings together expertise in both healthcare and venture capital and can help build industry-transforming companies with exponential impact and returns. The firm is currently investing from their first fund in Seed to Series B technology start-ups that address healthcare problems such as uncured and unmanaged disease, lack of access to care, poor quality and medical errors, health disparities, and unsustainable costs. The firm is open to global companies as 20% of the fund is invested internationally. The firm both co-invests and leads rounds with initial check sizes ranging from $250k-2.5M.

The firm invests in diagnosis, delivery of care (digital health), and technologies to enable drug discovery and development with the underlying thesis of data and AI. The firm does not invest in traditional pharma or therapeutics companies. The firm is indication-agnostic. Typically, the firm invests in companies generating revenue but is open to investing pre-revenue for particularly compelling technologies.

The firm often requires taking an observer or board seat. The firm does not have specific management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Leave a comment